We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: THG Surges After Raising Revenue Guidance

Mon, 26th Oct 2020 10:35

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.

----------

FTSE 100 - WINNERS

----------

Pearson, up 3.6%. UBS upgraded the education publisher to Buy from Neutral.

----------

AstraZeneca, up 1.1%. The Anglo-Swedish drugmaker late Friday said clinical trials for its AZD1222 coronavirus vaccine, being developed alongside Oxford University, has been resumed around the world, as regulators in the US, UK, Brazil, South Africa and Japan confirmed that it is safe to do so. The US Food & Drug Administration authorised the restart of the trials in the US, as they resumed in other countries in recent weeks, following the review of all safety data from trials in other regions.

----------

FTSE 100 - LOSERS

----------

Royal Dutch Shell 'A', down 1.6%, Shell 'B', down 1.5%. The oil major was tracking spot oil prices lower, quoted at USD40.78 a barrel Monday morning, down sharply from USD42.25 late Friday. Warring factions in Libya signed a countrywide ceasefire on Friday brokered by the United Nations. The ceasefire is poised to lead to more Libyan oil supply to the market at a time when demand is weak. "The return of just one million barrels per day of extra production to the world market has sent oil into a tailspin. It highlights how fragile sentiment is to the supply/demand balance of oil in international markets. A double-dip recession in Europe will add to the demand concerns," said Oanda Markets analyst Jeffery Halley.

----------

FTSE 250 - WINNERS

----------

Synthomer, up 2.5%. JPMorgan raised the speciality chemicals firm to Overweight from Neutral.

----------

FTSE 250 - LOSERS

----------

Beazley, down 2.5%. Morgan Stanley downgraded the insurer to Equal Weight from Overweight.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

THG Holdings, up 12%. The online retailing platform raised revenue guidance for 2020, following strong trading in the third quarter and continued momentum in the fourth quarter to date. THG said for the three months to the end of September, total revenue grew by 39% year-on-year to GBP378.1 million. The group reported growth across all businesses. The largest contributor was THG Beauty, which grew revenue by 45% to GBP157.5 million. However, it was the THG Lifestyle division which grew at the fastest percentage rate, with an 80% increase to GBP24.4 million. THG listed in London last month with a market capitalisation of GBP5.40 billion and at the time guided for annual revenue of GBP1.43 billion. As a result of the stronger quarterly performance, the group now expects revenue to be between GBP1.48 billion to GBP1.52 billion, reflecting a 30% to 33% increase from GBP1.14 billion the year before. "Longer-term excitement around the story is based on its Ingenuity platform which has been compared in some quarters to Ocado's online solution for global groceries firms. The Hut essentially picking up the IT and logistical requirements of the likes of PZ Cussons, Hotel Chocolat and Nestle," said AJ Bell's Russ Mould.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Advanced Oncotherapy, down 14% at 31.65 pence. The proton therapy provider said it intends to raise GBP7.7 million through a subscription, the proceeds of which will go towards strengthening the company's balance sheet and ensure its first LIGHT system is fully operational in 2021. The company said it will issue 25.7 million shares to clients of SI Capital and other investors at a price of 30p each. The issue price reflects a 18% discount to the company closing price on Friday at 37p. The newly issued shares will represent 7.7% of its enlarged issued share capital.

----------

Corcel, down 11% at 1.07 pence. The natural resource exploration and development company said it has raised GBP750,000 through the placing of 75 million shares at GBP0.01 per share. The placing price represents a 15% discount to Friday's closing price of 1.17 pence. London-based Corcel said the new cash will be used to exercise the option with Sinom Hong Kong Ltd to purchase the remaining AUD3.05 million - or GBP1.7 million - debt in Resource Mining Corp at a 65% discount, noting the the exercise of the option now entails the payment of AUD640,000 in cash and the issuance of 23.7 million shares to Sinom subsidiary Asia Pacific. The company added it will also use some of the proceeds to pursue additional opportunities in the battery metals space.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.